VTRS

Viatris Inc. NASDAQ

Healthcare ·Drug Manufacturers - Specialty & Generic ·US · viatris.com

$15.04

Mkt Cap $17.6B

52w Low $8.19 82.7% of range 52w High $16.47

50d MA $14.26 200d MA $11.83

P/E (TTM) -5.0x

EV/EBITDA -70.6x

P/B 1.2x

Debt/Equity 1.0x

ROE 84.1%

P/FCF 7.5x

RSI (14) —

ATR (14) —

Beta 0.82

50d MA $14.26

200d MA $11.83

Avg Volume 10.6M

About

Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; bio…

Recent Earnings

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	1M%	Guide ▲★
Feb 26, 2026	AMC	0.53	0.57	+7.1%	15.25	-0.6%	-2.1%	+3.0%	-2.4%	-3.5%	-4.7%	-15.0%	—
Nov 6, 2025	AMC	0.62	0.67	+7.9%	10.11	-0.2%	+0.1%	+0.6%	+10.8%	+8.9%	+7.9%	+9.7%	—
Aug 7, 2025	AMC	0.56	0.62	+11.5%	9.39	-0.1%	+3.3%	+5.0%	+7.8%	+10.9%	+13.8%	+11.6%	—
May 8, 2025	AMC	0.49	0.50	+1.6%	9.09	-0.8%	-3.5%	-1.4%	-3.3%	-7.4%	-3.3%	-3.1%	—
Feb 27, 2025	AMC	0.61	0.54	-11.5%	9.53	+1.0%	-3.1%	-2.1%	-1.7%	-0.5%	-0.2%	-8.6%	—
Nov 7, 2024	AMC	0.68	0.75	+10.8%	13.18	-0.8%	-1.7%	-0.7%	-1.9%	-1.4%	-4.2%	-2.9%	—
Aug 8, 2024	AMC	0.68	0.69	+1.8%	12.10	-0.2%	-2.6%	-4.4%	-4.4%	-5.8%	-3.6%	-8.0%	—
May 9, 2024	AMC	0.67	0.67	-0.4%	11.22	-0.3%	-0.5%	+1.2%	-0.7%	-1.3%	-1.8%	-6.3%	—
Feb 28, 2024	AMC	0.67	0.61	-9.0%	12.29	+0.6%	+0.7%	+2.4%	+0.6%	-0.1%	-0.7%	-2.8%	—
Nov 7, 2023	AMC	0.74	0.78	+5.4%	9.13	+4.1%	+1.0%	-0.8%	+0.8%	-2.0%	+1.0%	+6.9%	—
Aug 7, 2023	AMC	0.71	0.75	+5.6%	11.00	-0.3%	+1.4%	+2.4%	+1.5%	+3.2%	+1.7%	-8.0%	—
May 8, 2023	AMC	0.69	0.78	+13.0%	9.82	-0.8%	-0.8%	-2.3%	-4.7%	-5.5%	-4.6%	-1.1%	—

Recent Analyst Ratings

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Mar 24	Barclays	Maintains	Overweight → Overweight	—	$13.29	$13.21	-0.6%	+0.5%	+1.6%	+0.6%	-1.8%	-2.5%
Jan 28	Piper Sandler	Maintains	Neutral → Neutral	—	$13.12	$13.15	+0.2%	-1.1%	-0.4%	-0.2%	+4.3%	+4.3%
Jan 16	Argus	Upgrade	Hold → Buy	—	$12.84	$13.05	+1.6%	+0.2%	-1.4%	+1.6%	+3.1%	+2.9%
Mar 7	Jefferies	Maintains	Buy → Buy	—	$9.51	$9.51	+0.0%	+1.5%	-0.1%	-1.8%	-2.8%	-5.6%
Mar 5	Piper Sandler	Maintains	Neutral → Neutral	—	$9.37	$9.35	-0.2%	+1.2%	+1.5%	+3.0%	+1.4%	-0.3%
Feb 28	Barclays	Maintains	Underweight → Underweight	—	$9.53	$9.63	+1.0%	-3.1%	-2.1%	-1.7%	-0.5%	-0.2%
Feb 28	BofA Securities	Maintains	Underperform → Underperform	—	$9.53	$9.63	+1.0%	-3.1%	-2.1%	-1.7%	-0.5%	-0.2%
Dec 6	Piper Sandler	Maintains	Neutral → Neutral	—	$12.89	$12.97	+0.6%	-1.3%	-0.7%	-2.9%	-1.1%	-0.5%
Nov 8	Barclays	Maintains	Underweight → Underweight	—	$13.18	$13.07	-0.8%	-1.7%	-0.7%	-1.9%	-1.4%	-4.2%
Mar 28	Piper Sandler	Maintains	Neutral → Neutral	—	$11.83	$11.81	-0.2%	+0.9%	+0.9%	+0.9%	+1.6%	-0.6%
Nov 22	Piper Sandler	Maintains	Neutral → Neutral	—	$9.38	$9.36	-0.2%	-0.1%	+0.5%	-0.4%	-2.6%	-2.7%
Oct 23	BofA Securities	Downgrade	Neutral → Underperform	—	$9.30	$9.01	-3.1%	-4.1%	-2.0%	-3.5%	-3.3%	-5.7%
Jun 23	Barclays	Downgrade	Equal Weight → Underweight	—	$10.05	$9.77	-2.8%	-2.9%	-2.0%	-2.0%	-3.3%	-1.4%
Apr 25	Barclays	Downgrade	Overweight → Equal Weight	—	$9.33	$9.30	-0.3%	-1.6%	-2.5%	-0.8%	+0.0%	+0.3%
Apr 24	Barclays	Downgrade	Overweight → Equal Weight	—	$9.65	$9.52	-1.3%	-3.3%	-4.9%	-5.7%	-4.0%	-3.3%
Feb 28	Barclays	Maintains	Overweight → Overweight	—	$11.20	$11.29	+0.8%	+1.8%	+1.0%	-0.6%	-0.6%	-3.0%
Feb 17	BMO Capital	Downgrade	Outperform → Market Perform	—	$11.65	$11.53	-1.0%	+0.3%	-1.3%	-1.4%	-0.9%	-1.2%
Feb 1	Barclays	Maintains	Overweight → Overweight	—	$12.16	$12.06	-0.8%	+0.8%	+0.2%	+0.2%	-0.9%	-0.4%
Jan 27	Jefferies	Upgrade	Hold → Buy	—	$11.64	$11.90	+2.2%	+2.1%	+2.6%	+4.5%	+5.3%	+4.7%
Nov 15	JP Morgan	Maintains	Neutral → Neutral	—	$11.56	$11.66	+0.9%	-2.1%	-4.2%	-5.2%	-4.8%	-4.1%
Nov 10	UBS	Upgrade	Sell → Neutral	—	$10.83	$11.15	+3.0%	+4.7%	+5.6%	+6.7%	+4.5%	+2.3%
Nov 8	Piper Sandler	Upgrade	Underweight → Neutral	—	$10.97	$11.01	+0.4%	+1.2%	-1.3%	+3.4%	+4.3%	+5.4%
Oct 25	Barclays	Maintains	Overweight → Overweight	—	$9.53	$9.48	-0.5%	+2.6%	+4.6%	+3.6%	+5.7%	+6.3%
Oct 21	Jefferies	Maintains	Hold → Hold	—	$9.34	$9.28	-0.6%	+0.4%	+2.0%	+4.7%	+6.7%	+5.7%
Aug 9	BMO Capital	Maintains	Outperform → Outperform	—	$10.09	$10.03	-0.6%	+3.7%	+6.7%	+8.6%	+10.3%	+10.1%
Jun 14	UBS	Maintains	Sell → Sell	—	$10.77	$10.73	-0.4%	-4.2%	-0.7%	-4.5%	-2.9%	-1.6%
May 12	Goldman Sachs	Maintains	Neutral → Neutral	—	$10.39	$10.41	+0.2%	+4.4%	+6.6%	+7.2%	+10.4%	+8.5%
May 10	Piper Sandler	Downgrade	Neutral → Underweight	—	$10.48	$10.38	-1.0%	-0.2%	-0.9%	+3.5%	+5.7%	+6.3%
Mar 16	Piper Sandler	Maintains	Neutral → Neutral	—	$9.96	$10.11	+1.5%	+4.3%	+6.8%	+7.0%	+8.1%	+8.9%
Mar 10	Citigroup	Maintains	Neutral → Neutral	—	$10.28	$10.06	-2.1%	-1.6%	-2.5%	-4.6%	-3.1%	+1.1%
Mar 1	BofA Securities	Downgrade	Buy → Neutral	—	$11.01	$11.16	+1.4%	-7.8%	-4.8%	-5.4%	-7.4%	-10.3%
Mar 1	Raymond James	Downgrade	Outperform → Market Perform	—	$11.01	$11.16	+1.4%	-7.8%	-4.8%	-5.4%	-7.4%	-10.3%
Jun 15	Citigroup	Maintains	Neutral → Neutral	—	$15.63	$15.61	-0.1%	-2.1%	-2.6%	-6.1%	-8.8%	-8.2%
Mar 10	Morgan Stanley	Maintains	Equal Weight → Equal Weight	—	$13.91	$14.05	+1.0%	+1.1%	+1.4%	+3.2%	+5.5%	+4.5%
Mar 8	Goldman Sachs	Downgrade	Buy → Neutral	—	$13.91	$13.76	-1.1%	-0.6%	+0.0%	+1.1%	+1.4%	+3.2%
Mar 2	JP Morgan	Downgrade	Overweight → Neutral	—	$14.72	$14.55	-1.2%	-2.9%	-5.7%	-7.7%	-5.5%	-6.0%
Feb 23	Raymond James	Maintains	Outperform → Outperform	—	$15.50	$15.74	+1.5%	-1.8%	-1.3%	-2.9%	-4.2%	-5.0%
Jan 25	Raymond James	Maintains	Outperform → Outperform	—	$17.43	$17.26	-1.0%	-1.1%	-2.0%	-3.3%	-1.4%	-2.5%

Recent Filings

8-K · 8.01 !! High

Viatris Inc. -- 8-K 8.01: Material Event / Announcement

Viatris will hold an earnings call today at 8:30 a.m. ET to discuss Q4 and full-year 2025 financial results, providing investors opportunity to hear management commentary and guidance.

Feb 26

8-K

Viatris Inc. -- 8-K Filing

Viatris Inc. filed an 8-K that indicates the company meets emerging growth company criteria under SEC regulations, potentially offering regulatory relief and disclosure accommodations for the pharmaceutical manufacturer.

Feb 3

Data updated apr 27, 2026 8:27am · Source: massive.com